Unknown

Dataset Information

0

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.


ABSTRACT:

Background

The 2-drug regimen dolutegravir + lamivudine was noninferior to dolutegravir + tenofovir disoproxil fumarate/emtricitabine in achieving HIV-1 RNA <50 copies/mL in treatment-naive adults in the 48-week primary analysis of the GEMINI trials. We present results from the prespecified 96-week secondary analyses.

Setting

One hundred eighty-seven centers in 21 countries.

Methods

GEMINI-1 and GEMINI-2 are identical, double-blind phase III studies. Participants with screening HIV-1 RNA ?500,000 copies/mL were randomized 1:1 to once-daily dolutegravir + lamivudine or dolutegravir + tenofovir disoproxil fumarate/emtricitabine.

Results

At week 96, dolutegravir + lamivudine (N = 716) was noninferior to dolutegravir + tenofovir disoproxil fumarate/emtricitabine (N = 717) in achieving HIV-1 RNA <50 copies/mL (Snapshot algorithm; -10% noninferiority margin) in the pooled analysis (proportion of responders, 86.0% vs 89.5%, respectively; adjusted treatment difference [95% CI], -3.4% [-6.7 to 0.0007]), GEMINI-1 (-4.9% [-9.8 to 0.03]), and GEMINI-2 (-1.8% [-6.4 to 2.7]). Proportions of participants in the HIV-1 RNA ?50 copies/mL Snapshot category were largely unchanged from week 48 to 96. Eleven participants taking dolutegravir + lamivudine and 7 taking dolutegravir + tenofovir disoproxil fumarate/emtricitabine met confirmed virologic withdrawal criteria through week 96; none had treatment-emergent resistance mutations. Dolutegravir + lamivudine had a lower rate of drug-related adverse events than dolutegravir + tenofovir disoproxil fumarate/emtricitabine (19.6% vs 25.0%; relative risk ratio, 0.78; 95% CI: 0.64 to 0.95). Renal and bone biomarker changes favored dolutegravir + lamivudine.

Conclusions

Consistent with 48-week data, dolutegravir + lamivudine demonstrated long-term, noninferior efficacy vs dolutegravir + tenofovir disoproxil fumarate/emtricitabine without increased risk of treatment-emergent resistance, supporting its use in treatment-naive HIV-1-infected individuals.

SUBMITTER: Cahn P 

PROVIDER: S-EPMC7043729 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.

Cahn Pedro P   Madero Juan Sierra JS   Arribas José R JR   Antinori Andrea A   Ortiz Roberto R   Clarke Amanda E AE   Hung Chien-Ching CC   Rockstroh Jürgen K JK   Girard Pierre-Marie PM   Sievers Jörg J   Man Choy Y CY   Urbaityte Rimgaile R   Brandon Daisy J DJ   Underwood Mark M   Tenorio Allan R AR   Pappa Keith A KA   Wynne Brian B   Gartland Martin M   Aboud Michael M   van Wyk Jean J   Smith Kimberly Y KY  

Journal of acquired immune deficiency syndromes (1999) 20200301 3


<h4>Background</h4>The 2-drug regimen dolutegravir + lamivudine was noninferior to dolutegravir + tenofovir disoproxil fumarate/emtricitabine in achieving HIV-1 RNA <50 copies/mL in treatment-naive adults in the 48-week primary analysis of the GEMINI trials. We present results from the prespecified 96-week secondary analyses.<h4>Setting</h4>One hundred eighty-seven centers in 21 countries.<h4>Methods</h4>GEMINI-1 and GEMINI-2 are identical, double-blind phase III studies. Participants with scree  ...[more]

Similar Datasets

| S-EPMC6808746 | biostudies-literature
| S-EPMC8654248 | biostudies-literature
| S-EPMC4645960 | biostudies-literature
| S-EPMC5515053 | biostudies-literature
| S-EPMC3694319 | biostudies-literature
| S-EPMC5961309 | biostudies-literature
| S-EPMC10976086 | biostudies-literature
| S-EPMC3685599 | biostudies-literature
| S-EPMC7185366 | biostudies-literature
| S-EPMC10477137 | biostudies-literature